Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Narrative update of clinical trials with antihypertensive drugs in children and adolescents

J. Redon, T. Seeman, D. Pall, L. Suurorg, K. Kamperis, S. Erdine, E. Wühl, G. Mancia

. 2022 ; 9 (-) : 1042190. [pub] 20221121

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc22031234

INTRODUCTION: To date, our knowledge on antihypertensive pharmacological treatment in children and adolescents is still limited because there are few randomized clinical trials (CTs), hampering appropriate management. The objective was to perform a narrative review of the most relevant aspects of clinical trials carried out in primary and secondary hypertension. METHODS: Studies published in PubMed with the following descriptors: clinical trial, antihypertensive drug, children, adolescents were selected. A previous Cochrane review of 21 randomized CTs pointed out the difficulty that statistical analysis could not assess heterogeneity because there were not enough data. A more recent meta-analysis, that applied more stringent inclusion criteria and selected 13 CTs, also concluded that heterogeneity, small sample size, and short follow-up time, as well as the absence of studies comparing drugs of different classes, limit the utility. RESULTS: In the presented narrative review, including 30 studies, there is a paucity of CTs focusing only on children with primary or secondary, mainly renoparenchymal, hypertension. In trials on angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs) and diuretics, a significant reduction of both SBP and DBP in mixed cohorts of children with primary and secondary hypertension was achieved. However, few studies assessed the effect of antihypertensive drugs on hypertensive organ damage. CONCLUSIONS: Given the increasing prevalence and undertreatment of hypertension in this age group, innovative solutions including new design, such as 'n-of-1', and optimizing the use of digital health technologies could provide more precise and faster information about the efficacy of each antihypertensive drug class and the potential benefits according to patient characteristics.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031234
003      
CZ-PrNML
005      
20230127131107.0
007      
ta
008      
230119s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fcvm.2022.1042190 $2 doi
035    __
$a (PubMed)36479567
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Redon, Josep $u INCLIVA Research Institute, CIBERObn Institute of Health Charles III, University of Valencia, Madrid, Spain
245    10
$a Narrative update of clinical trials with antihypertensive drugs in children and adolescents / $c J. Redon, T. Seeman, D. Pall, L. Suurorg, K. Kamperis, S. Erdine, E. Wühl, G. Mancia
520    9_
$a INTRODUCTION: To date, our knowledge on antihypertensive pharmacological treatment in children and adolescents is still limited because there are few randomized clinical trials (CTs), hampering appropriate management. The objective was to perform a narrative review of the most relevant aspects of clinical trials carried out in primary and secondary hypertension. METHODS: Studies published in PubMed with the following descriptors: clinical trial, antihypertensive drug, children, adolescents were selected. A previous Cochrane review of 21 randomized CTs pointed out the difficulty that statistical analysis could not assess heterogeneity because there were not enough data. A more recent meta-analysis, that applied more stringent inclusion criteria and selected 13 CTs, also concluded that heterogeneity, small sample size, and short follow-up time, as well as the absence of studies comparing drugs of different classes, limit the utility. RESULTS: In the presented narrative review, including 30 studies, there is a paucity of CTs focusing only on children with primary or secondary, mainly renoparenchymal, hypertension. In trials on angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs) and diuretics, a significant reduction of both SBP and DBP in mixed cohorts of children with primary and secondary hypertension was achieved. However, few studies assessed the effect of antihypertensive drugs on hypertensive organ damage. CONCLUSIONS: Given the increasing prevalence and undertreatment of hypertension in this age group, innovative solutions including new design, such as 'n-of-1', and optimizing the use of digital health technologies could provide more precise and faster information about the efficacy of each antihypertensive drug class and the potential benefits according to patient characteristics.
590    __
$a NEINDEXOVÁNO
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Seeman, Tomas $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University Prague, Prague, Czechia
700    1_
$a Pall, Dénes $u Department of Medical Clinical Pharmacology, University of Debrecen, Debrecen, Hungary
700    1_
$a Suurorg, Lagle $u Tallinn Children's Hospital, Tallinn, Estonia
700    1_
$a Kamperis, Konstantinos $u Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
700    1_
$a Erdine, Serap $u Hypertension and Atherosclerosis Center, Marmara University School of Medicine, Istanbul, Turkey
700    1_
$a Wühl, Elke $u Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany
700    1_
$a Mancia, Giuseppe $u University of Milano-Bicocca, Milan, Italy
773    0_
$w MED00198704 $t Frontiers in cardiovascular medicine $x 2297-055X $g Roč. 9, č. - (2022), s. 1042190
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36479567 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230127131059 $b ABA008
999    __
$a ok $b bmc $g 1889419 $s 1182567
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 9 $c - $d 1042190 $e 20221121 $i 2297-055X $m Frontiers in cardiovascular medicine $n Front Cardiovasc Med $x MED00198704
LZP    __
$a Pubmed-20230119

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...